TOMM22

Across TCGA pan-cancer cohorts, TOMM22 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TOMM22 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher TOMM22 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TOMM22 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

COAD, CCRCC, and HNSC are the cancer types where TOMM22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	1.000	0.917	.020	30	view →
CCRCC	DFS	Median	III,IV	0.400	0.713	.010	18	view →
HNSC	OS	Quartile	IV	0.517	0.819	.014	13	view →
LUAD	DFS	Median	II,III,IV	0.966	0.740	.008	11	view →
GBM	OS	Tertile	All	0.932	0.737	.024	6	view →
LSCC	DFS	Median	All	0.615	0.929	.025	1	view →
PDAC	DFS	Quartile	III,IV	0.651	0.814	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TOMM22–COAD (DFS)

Open the COAD breakdown →